Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer.

Détails

Ressource 1Télécharger: BIB_34BF0625B509.P001.pdf (2528.86 [Ko])
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_34BF0625B509
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer.
Périodique
Genes and Development
Auteur⸱e⸱s
Akkari L., Gocheva V., Quick M.L., Kester J.C., Spencer A.K., Garfall A.L., Bowman R.L., Joyce J.A.
ISSN
1549-5477 (Electronic)
ISSN-L
0890-9369
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
30
Numéro
2
Pages
220-232
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
Proteases are important for regulating multiple tumorigenic processes, including angiogenesis, tumor growth, and invasion. Elevated protease expression is associated with poor patient prognosis across numerous tumor types. Several multigene protease families have been implicated in cancer, including cysteine cathepsins. However, whether individual family members have unique roles or are functionally redundant remains poorly understood. Here we demonstrate stage-dependent effects of simultaneously deleting cathepsin B (CtsB) and CtsS in a murine pancreatic neuroendocrine tumor model. Early in tumorigenesis, the double knockout results in an additive reduction in angiogenic switching, whereas at late stages, several tumorigenic phenotypes are unexpectedly restored to wild-type levels. We identified CtsZ, which is predominantly supplied by tumor-associated macrophages, as the compensatory protease that regulates the acquired tumor-promoting functions of lesions deficient in both CtsB and CtsS. Thus, deletion of multiple cathepsins can lead to stage-dependent, compensatory mechanisms in the tumor microenvironment, which has potential implications for the clinical consideration of selective versus pan-family cathepsin inhibitors in cancer.
Mots-clé
Animals, Apoptosis/genetics, Carcinogenesis/genetics, Carcinoma, Neuroendocrine/enzymology, Carcinoma, Neuroendocrine/genetics, Cathepsins/genetics, Cathepsins/metabolism, Disease Models, Animal, Gene Deletion, Gene Expression Regulation, Neoplastic, Gene Knockout Techniques, Macrophages/enzymology, Mice, Mice, Inbred C57BL, Neoplasm Invasiveness/genetics, Neovascularization, Pathologic/enzymology, Neovascularization, Pathologic/genetics, Pancreatic Neoplasms/enzymology, Pancreatic Neoplasms/genetics
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/02/2016 21:00
Dernière modification de la notice
20/08/2019 14:21
Données d'usage